Skip to main content
All lobbying filings

ALSTON & BIRD LLP

Lobbying for TRAVERE THERAPEUTICS · Prescription pharmaceutical manufacturer of medications.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Pharmacy

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs. Most-Favored Nation and International Reference Pricing proposals. PDUFA/regulatory review process.

Medical/Disease Research/Clinical Labs

H.R.10571, Surge to Save Newborns Act.

Taxation/Internal Revenue Code

H.R.1414, Camerons Law, to restore the amount of the Orphan Drug Tax Credit.

Trade (domestic/foreign)

Treatment of orphan drugs under tariff proposals.

Health Issues

Support for H.R.946, Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. H.R.10571, Surge to Save Newborns Act. H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Support of reauthorization of priority review voucher program. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs.

Medicare/Medicaid

H.R.1518, New Era of Preventing End-Stage Kidney Disease Act. Pub. L. No. 119-21, One Big Beautiful Bill Act, provisions regarding orphan drugs, Medicare and Medicaid.

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem